A Phase II Safety, Efficacy, and Feasibility Study of Neoadjuvant ZD1839 (IRESSA) [gefitinib] in Resectable Esophageal Cancer

Trial Profile

A Phase II Safety, Efficacy, and Feasibility Study of Neoadjuvant ZD1839 (IRESSA) [gefitinib] in Resectable Esophageal Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Oct 2013

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Oesophageal cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 15 Oct 2013 Additional lead trial investigator added as reported by ClinicalTrials.gov record.
    • 25 Jan 2008 Status changed from recruiting to discontinued.
    • 22 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top